title: Effects of BRAF(V600E) mutation on Na(+)/I(-) symporter expression in papillary thyroid carcinoma.
abstract: Radioiodine ablation (RIA) therapy is one of the most important treatments for papillary thyroid carcinoma (PTC), but some patients who received (131)I have radioiodine-refractory disease caused by the decreased expression of the Na(+)/I(-) symporter (NIS). BRAF(V600E) mutation is one possible risk factor that can disturb the NIS expression, but the roles are unclear in clinical practice. This research discussed the association of BRAF(V600E) mutation and NIS expression in PTC tissue and the clinical implications in RIA therapy. 134 PTC samples were collected between June 2013 and June 2014 from Tongji Hospital affiliated to Tongji Medical College, and their clinical characteristics were analyzed. RT-PCR was used to detect the BRAF(V600E) mutation from formalin-fixed paraffin-embedded samples, and immunohistochemistry was applied to detect the NIS expression. IPP software was used to calculate the relative expression quantity of NIS. We found that there was no significant correlation between the absorbance (A) values of NIS and clinicopathologic features in these cases, even thyroid stimulating hormone. BRAF(V600E) mutation showed inhibitory effect on the NIS expression without statistically significant difference in all PTC cases (β=-0.0195, P=0.085), but in the subgroup without hashimoto's thyroiditis (HT), BRAF(V600E) mutation could significantly inhibit the NIS expression (β=-0.0257, P=0.046). The results indicate that BRAF(V600E) mutation is correlated with a lower expression of NIS in PTCs without HT, suggesting the radioiodine-refractory effects during RIA therapy in these patients.
authors.affiliation: Department of Thyroid and Breast Surgery, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
authors.forename: Hong
authors.initials: H
authors.lastname: Dong
authors.affiliation: Department of Thyroid and Breast Surgery, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
authors.forename: Wen-Zhuang
authors.initials: WZ
authors.lastname: Shen
authors.affiliation: Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Wuhan, 430030, China.
authors.forename: Yu-Jing
authors.initials: YJ
authors.lastname: Yan
authors.affiliation: Department of Thyroid and Breast Surgery, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
authors.forename: Ji-Lin
authors.initials: JL
authors.lastname: Yi
authors.affiliation: Department of Thyroid and Breast Surgery, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. zhanglin3@medmail.com.cn.
authors.forename: Lin
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000328:Adult; D002277:Carcinoma / Q000235:genetics* / Q000378:metabolism; D002291:Carcinoma, Papillary; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics*; D027981:Symporters / Q000235:genetics / Q000378:metabolism*; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000235:genetics* / Q000378:metabolism; D000099209:Sodium-Iodide Symporters
chemical_list: D048493:Proto-Oncogene Proteins B-raf; D027981:Symporters; D000099209:Sodium-Iodide Symporters; C482119:BRAF protein, human
keywords: BRAFV600E mutation; Na+/I- symporter; papillary thyroid carcinoma; radioiodine therapy
references.citation: J Surg Res. 2013 Jun 1;182(1):85-93
references.pmid: 22998776
references.citation: Eur Cytokine Netw. 2013 Mar;24(1):69-74
references.pmid: 23614931
references.citation: Lancet Diabetes Endocrinol. 2014 Oct;2(10):830-42
references.pmid: 24898835
references.citation: Endocr Relat Cancer. 2006 Mar;13(1):257-69
references.pmid: 16601293
references.citation: Nat Rev Endocrinol. 2011 Aug 09;7(10):589-95
references.pmid: 21826102
references.citation: Endocr Rev. 2014 Feb;35(1):106-49
references.pmid: 24311738
references.citation: Oncol Lett. 2013 Jan;5(1):368-372
references.pmid: 23255951
references.citation: J Clin Endocrinol Metab. 2006 Aug;91(8):2892-9
references.pmid: 16684830
references.citation: Lancet. 2013 Mar 23;381(9871):1058-69
references.pmid: 23668556
references.citation: Cell Growth Differ. 1998 Jan;9(1):97-103
references.pmid: 9438393
references.citation: Horm Cancer. 2014 Dec;5(6):363-73
references.pmid: 25234361
references.citation: J Am Med Assoc. 1946 Dec 7;132(14):838-47
references.pmid: 20274882
references.citation: Endocrinol Metab Clin North Am. 2008 Jun;37(2):457-80, x
references.pmid: 18502337
references.citation: Thyroid. 2010 Nov;20(11):1235-45
references.pmid: 21062195
references.citation: Oncol Res. 1999;11(9):421-7
references.pmid: 10821536
references.citation: Cancer Res. 2009 Nov 1;69(21):8317-25
references.pmid: 19861538
references.citation: Surg Clin North Am. 2014 Jun;94(3):573-86
references.pmid: 24857577
references.citation: J Clin Endocrinol Metab. 2007 Jul;92(7):2840-3
references.pmid: 17488796
references.citation: Arch Surg. 2004 Apr;139(4):390-4; discussion 393-4
references.pmid: 15078706